Background
Tumor recurrence is one of the biggest challenges in breast cancer, because it often leads to an incurable disease. Therapeutic resistance, the major mechanism underlying tumor recurrence, raises the question of whether conventional anticancer therapies target the correct cells. The existence of a subpopulation of tumor cells with stem cell-like characteristics, such as very slow replication and resistance to standard chemotherapy, poses a new concept to account for the phenomena of drug resistance and tumor recurrence. It was not until 1994 that cancer stem cells (CSCs, also known as tumor-initiating cells) were first identified in human acute myeloid leukemia malignancies [
1]. Subsequent studies have identified CSCs in solid tumors, including breast [
2], prostate [
3,
4], brain [
5], colon [
6], and pancreas [
7,
8]. For example, breast cancer stem cells are characterized by low levels of heat stable antigen (CD24) and high levels of hyaluronan receptor (CD44) expression. This subpopulation of cells has the ability to self-renew, and to initiate tumor formation, and is intrinsically resistant to therapy. The cancer stem cell hypothesis has fundamental clinical implications, as current treatment strategies may affect the bulk of the tumor cells but leave CSCs behind, serving as a reservoir for disease recurrence and metastasis [
9‐
11]. Therefore, the elucidation of molecular pathways, which regulate self-renewal activity of CSCs and their interaction with niche, will provide potential therapeutic targets.
Although the CSCs hypothesis suggests that tumors can arise from stem or progenitor cells, studies from many laboratories indicate that epithelial-mesenchymal transition (EMT) can endow cells with stem-cell like characteristics [
12‐
15]. EMT is an embryonic developmental process in which epithelial cells lose expression of many markers of differentiation, acquire fibroblast-like properties and show reduced intercellular adhesion and increased motility [
16‐
18]. EMT has been recognized not only as a physiological mechanism for development and tissue remodeling, but also as a pathological mechanism in the progression of various diseases including inflammation, fibrosis and cancer [
16,
17]. Weinberg and his colleagues showed that induction of EMT in immortalized human mammary epithelial cells results in an increased ability to form tumorspheres, and in the expression of stem cell-like markers [
13]. Specifically, cells with CD44+CD24low phenotype, which yielded tumor formation with as few as 100 cells (compared with that the control), were found significant increased when cells were treated with transforming growth factor-beta or were overexpressing the key EMT inducers, Snail and Twist. These data indicate that EMT endows tumor cells with stem cell-like properties. Consistent with this finding, tumor cells resistant to chemo- and endocrine therapies activate the EMT program, which results in the expansion of CSCs with CD44
+CD24
low expression [
13,
14,
19]. However, it is unclear how the activation of the EMT program contributes to the expansion of CSCs with CD44
+CD24
low traits.
A hallmark of EMT is the loss of
E-cadherin expression [
16‐
18]. E-cadherin is a cell-cell adhesion molecule that participates in homotypic, calcium-dependent interactions to form epithelial adherent junctions [
20,
21]. Loss of E-cadherin expression is often correlated with the tumor grade and stage [
20,
21], because it results in the disruption of cell-cell adhesion and an increase in nuclear β-catenin, thus leading to cell growth and survival. On one hand, β-catenin is an essential component of adherent junctions, where it provides the link between E-cadherin and β-catenin and modulates cell-cell adhesion and cell migration [
22]. On the other hand, β-catenin also functions as a transcription cofactor with T cell factor (TCF). In unstimulated cells, the level of free cytoplasmic β-catenin is kept low through a destruction complex, which consists of axin, adenomatous polyposis coli (APC), GSK-3β and casein kinase (CKI). GSK-3β phosphorylates β-catenin and triggers its ubiquitination and degradation by β-Trcp. In the presence of Wnt ligands, Wnts bind to frizzled and LRP5/6 receptor complex to inactivate GSK-3β in the destruction complex. This, in turn, results in the stabilization and nuclear accumulation of β-catenin and leads to the activation of the Wnt/β-catenin signaling pathway [
22], which has been implicated in stem cell maintenance and self-renewal.
In this study, we found that the expression of Twist induced EMT and the expansion of the CD44highCD24low subpopulation, which is associated with CSC properties. We showed that β-catenin and Akt pathways were activated in these Twist-overexpressing transfectants. The nuclear accumulation of β-catenin correlated with the expression of CD44. Knockdown of β-catenin expression and inhibition of the Akt pathway significantly decreased the expression of CD44. Together, our results indicate that the activation of β-catenin and the Akt pathway is required for the sustention of cancer stem cell-like traits generated by EMT.
Methods
Cell cultures, transfections and reporter assays
MCF7 and Hela cells were cultured with DMEM medium supplemented with 10% fetal bovine serum in a humidified CO2 incubator at 37°C. To generate Twist-expression stable transfectants, Hela and MCF7 cells were transfected with pcDNA3-Twist1, and stable clones were selected with 1000 μg/ml of G418 (CALBIOCHEM) for 4 weeks.
TOPflash or FOPflash plasmid (Upstate, Lake Placid, NY) was transiently transfected into cells with Fugene 6 (Roche, Indianapolis, IN). For measuring the transcription of CD44, pGL3-CD44P was also expressed in cells. To normalize transfection efficiency, cells were also co-transfected with 0.1 μg of the pRL-CMV (Renilla luciferase). Forty-eight hours after transfection, luciferase activity was measured using the Dual-Luciferase Assay kit (Promega, Madison, WI). Three independent experiments were performed, and the calculated means and standard deviations are presented.
To knock down the expression of β-catenin, cells were seeded on 6-well plates and transfected with pGL3-CD44P, along with validated human β-catenin siRNA (Dharmacon) at a final concentration of 100 nM using X-tremeGENE siRNA transfection reagent (Roche) following manufacturer's instructions. After 36 h of transfection, cells were treated with or without PI3K/Akt inhibitors wortmannin (100 nM) for overnight. Luciferase activity was measured as described above. All experiments were performed at least three times in triplicate.
Commercial antibodies used in this study were presented in Table
1.
Table 1
Antibodies used in this study
Twist | Twist | Rabbit | Cell signaling |
Snail | Snail | Rat | Cell signaling |
N-cadherin | N-cadherin | Mouse | Upstate |
Fibronectin Ab-11 | Fibronectin | Mouse | Neo Markers |
Vimentin Ab-2 | Vimentin | Mouse | Neo Markers |
γ-catenin | γ-catenin | Mouse | BD transduction |
E-cadherin | E-cadherin | Mouse | BD transduction |
ZO-1 | ZO-1 | Rabbit | Abcam |
p-GSK-3β (Ser9) | GSK-3β (Ser9) | Mouse | Upstate |
GSK-3β | GSK-3β | Goat | Santa Cruz |
p-Akt (Ser473) | Akt (Ser473) | Rabbit | Cell signaling |
Akt | Akt1,2,3 | Rabbit | Cell signaling |
p-β-catenin(Ser33/37/Thr41) | β-catenin (Ser33/37/Thr41) | Rabbit | Cell signaling |
β-catenin | β-catenin | Rabbit | Abcam |
β-tubulin | β-tubulin | Mouse | Sigma |
Anti-FLAG M2 | FLAG-tag | Mouse | Sigma |
CD44 | CD44 | Mouse | Cell signaling |
PE-Cy7-CD44 | CD44 | Rat | eBioscience |
PE-CD24 | CD24 | Mouse | eBioscience |
Western Blot Analysis
To prepare the whole-cell extract, cells were washed with PBS once and harvested by scraping them in 1 ml lyses buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl, 0.2 mM EDTA, 0.2% NP-40, 10% Glycerin, 1M β-Me, 1 μg/ml Aprotin, 0.5 μg/ml Leupetin, 0.1 mM Na3VO4, 0.5 mM 4NPP, 0.5 mM NaF, and protease inhibitors). Cellular lysates were centrifuged at 13,200 × g for 5 min at 4°C. Protein content was determined by the Bradford assay (Bio-Rad Laboratories, Hercules, CA). The extracted proteins were separated in a 10-12% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Amersham Bioscience). The membranes were first blocked with 5% (w/v) nonfat dry milk in PBST and then probed with the indicated primary antibodies with gentle shaking at 4°C overnight. After washing the membranes four times, the membranes were incubated with the appropriate peroxidase-conjugated secondary antibodies for 1 hour. The signals were detected using an enhanced chemiluminescence kit (Amersham Biosciences).
Immunofluorescent Analysis
Cells were grown on glass chamber slides fixed with 4% paraformaldehyde in PBS for 30 min. Then cells were permeabilized in 0.1% Triton X-100 for 30 min and blocked with 0.5% bovine serum albumin in PBS for 30 min at room temperature. After washing with PBS, the cells were incubated with specific primary antibodies for 1 hour at room temperature. After being washed with PBST, the cells were incubated with appropriate fluorescein isothiocyanate-conjugated secondary antibodies and then stained with 4', 6-diamidino-2-phenylindole (DAPI) (Roche Diagnostics). The images were visualized with an Olympus microscope.
Flow Cytometry Analysis
Flow Cytometry Analysis was performed as described previously [
23]. Cells were harvested by trypsinization and washed twice with PBS. The cells then were fixed and stained with monoclonal antibodies against CD44, CD24 or an isotype IgG, labeled with Alexa 488-conjugated secondary antibody, and subjected to flow cytometric analysis using a flow cytometer (BD-LSR model, Becton-Dickinson, San Jose, CA).
Tumorsphere Culture
Single-cell suspensions were suspended at a density of 4,000 cells per milliliter in Dulbecco's modified Eagle's medium/F-12 (Twist/MCF7, MCF7) or Dulbecco's modified Eagle's medium (Twist/HeLa; HeLa) and seeded into six-well plates (2.0 mL per plate) coated with 1.2% poly-Hema. Suspension cultures were continued for 1-2 weeks (7-day for Hela and Twist/Hela cells; 12-day for MCF7 and Twist/MCF7 cells) until the formation of tumorspheres. Colonies were counted at 10 different views under microscope. Experiments were repeated three times with duplication in each experiment.
Cellular Fractionation Analysis
Cellular fractionation was performed as described by Abmayr et al with minor modifications [
24]. Briefly, cells were harvested with trypsinization and washed twice with phosphate-buffered saline (137 mM NaC1, 2.7 mM KC1, 4.3 mM Na
2HPO
4, 1.4 mM KH
2PO
4, pH 7.4). Cells were rapidly washed once with hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl
2, 10 mM KCl, 0.2 mM PMSF, and 0.5 mM DTT), re-suspended with 3 packed cell volume of hypotonic buffer and allowed to swell on ice for 10 min. Cells were then homogenized with 20 strokes on Dounce homogenizer (type B pestle) to ensure that >95% of cells were lyzed. After centrifugation at 4°C with 3300 × g for 15 min, Supernatant was saved for S-100 cytoplasmic extract preparation. The nuclear pellet was washed once with lysis buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl, 0.2 mM EDTA, 0.2% NP-40, 10% Glycerin, and protease cocktail) and suspected in the same buffer. After brief sonication, the suspension was spin at 13,200 × g for 20 min and supernatant was saved as the nuclear fraction. To prepare the membrane and cytoplasmic fractions, the supernatant saved above was centrifuged at 100,000 × g for 20 minutes at 4°C, Supernatant was saved as the cytoplasmic fraction. The pellet was re-suspended in lysis buffer containing 1% of Trition X-100 and save as the membrane fraction.
Equal proteins from these three fractions for parental and Twist-overexpressing cells were used for western blotting analysis.
Preparation of Wnt3a Conditioned-Medium
Wnt3A-conditioned media was prepared as described by Willert et al [
25]. Briefly, stable murine L-cells (ATCC, Manassas, VA) that overexpress Wnt3A were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% L-glutamine, and 0.4 mg/ml Geneticin. To obtain Wnt3A-conditioned media, cells were seeded into 100-mm dishes and cultured for 4 days in growth medium without G418, the medium was removed and sterile-filtered. Fresh medium was added to the plates and cultured for an additional 3 days. The medium was then removed, sterile-filtered and combined with the initial batch of cultured media, and stored at -80°C in aliquots as Wnt3A conditioned medium.
Statistical Analysis
The experiments were repeated at least two times. Results are expressed as mean ± SD or SEM as indicated. An independent Student's t-test was performed to analyze the luciferase assay and other analyses. p < 0.05 was considered statistically significant.
Discussion
In this study, we showed that the expression of Twist induced EMT in Hela and MCF7 cells, and that accompanied the increased stem cell-like properties and the upregulation of CD44. We found that the upregulation of CD44 was mediated by the activation of β-catenin and Akt pathways in these cells; inhibition of both pathways synergistically suppressed the upregulation of CD44. Our study provides several new insights into the regulation of EMT and cell differentiation program. First, our results indicate that the activation of β-catenin and Akt pathways is critical for the maintenance of the stem cell-like properties associated with EMT (Figure
7b). The gain-of-function of stem cell-like properties in EMT may confer tumor cells the survivability against chemo- and endocrine therapies, in addition to a distinct advantage for invasion and metastasis [
13,
14,
19]. However, the molecular link between EMT and the gain of CSCs properties is unclear; whether a shared signaling pathway regulates both processes remains to be determined. The Wnt/β-catenin pathway mediates a wide variety of processes, including cell proliferation, migration, differentiation, adhesion and apoptosis. It is critical for homeostatic stem cell renewal. For example, Wnt signaling is necessary for maintenance of stem cells in the intestinal crypts [
31]. Treating prostate cancer cells with stem cell-like characteristics with WNT inhibitors reduced both the size of tumorspheres and the ability of self-renewal, whereas Wnt3a stimulates them [
32]. Consistent with previous reports [
12‐
15], we found that over-expression of Twist induced EMT in Hela and MCF7 cells, which accompanied the gain-of-function of stem cell-like properties, such as high levels of ALDH1 expression, tumorsphere-formation and high levels of CD44. We further showed that the β-catenin pathway was activated as the membrane-bound and phosphorylated β-catenin was significantly decreased in Twist-overexpressing Hela and MCF7 cells. E-cadherin is known to anchor and to sequester β-catenin in the membrane and prevent it from activation; the activation of β-catenin signaling may result from the downregulation of E-cadherin at EMT. CD44 has been shown to be a downstream target of the β-catenin signaling pathway. We found that elevated CD44 correlated with the activation of β-catenin in Twist-overexpressing cells. Interestingly, the activation of the β-catenin pathway was not optimal, as treatment of Wnt3a can further induce the activation of β-catenin and the induction of CD44, suggesting that EMT initiates and primes β-catenin activation and this activation can be further synergized by the Wnt ligand from the tumor microenvironment.
The expression of Twist also has been shown to activate the Akt pathway to promote migration, invasion and paclitaxel resistance [
29]. The activation of Akt phosphorylated and suppressed GSK-3β, which is the major kinase for the phosphorylation of β-catenin and Snail [
30,
33]. The phosphorylation of these molecules by GSK-3β results in the consequent degradation of β-catenin and Snail by E3 ligase β-Trcp [
30,
33]. Consistent with these findings, we discovered that Akt was activated in Twist-overexpressing cells, which lead to the phosphorylation and suppression of GSK-3β and resulted in the significant protein stabilization of β-catenin and Snail in these cells. When E-cadherin is downregulated at EMT, the released cytoplasmic β-catenin is still subjected to GSK-3β mediated phosphorylaton and degradation. Thus, additional activation of the Akt pathway is necessary to prevent this process and facilitates the nuclear translocation and activation of β-catenin. This speculation is consistent with the fact that EMT also correlates with the presence of β-catenin in the nucleus [
34]. Thus, activation of β-catenin and Akt pathways is a synergistic event at EMT and is critical for generating high-grade invasive cells with stem cell-like features (Figure
7b).
Second, our results suggest that targeting the β-catenin and Akt pathways can suppress the stem cell-like properties associated with EMT. CSCs are often resistant to common drugs
in vivo and
in vitro when compared with the majority of the cancer cell population, raising the question of whether traditional therapy only "debulks" tumors, leaving CSCs to repopulate the original tumor and which results in disease recurrence. Consistent with these findings, Cheng and her colleagues showed that the residual breast tumor cell populations that survived after conventional treatment were enriched for the subpopulation of cells with both tumor stem cell-like features and EMT characteristics [
9,
11]. Thus, more effective therapies will require the selective targeting of this crucial cell population. The elucidation of molecular pathways underlying the regulation of CSC self-renewal and survival is crucial to the success of this goal. In our study, we found that either the knockdown of β-catenin expression or the suppression of the Akt pathway by wortmannin inhibited CD44 expression. Moreover, the combination of both chemical suppression and siRNA knockdown significantly suppressed the expression of CD44, indicating the synergistic effect of these two pathways in maintaining the stem cell-like properties associated with EMT. Gupta et al. recently implemented a chemical screen and discovered compounds showing selective toxicity for breast CSCs, including salinomycin [
35]. It would be interesting to test whether Salinomycin inhibits the activation of β-catenin and Akt pathways in the near future.
Conclusion
In summary, we showed that the activation of β-catenin and Akt is critical for the maintenance of CD44 expression associated with EMT. Targeting these pathways, in conjunction with currently used conventional treatments, may provide a new therapeutic strategy for eliminating surviving tumor cells to prevent recurrence and to improve long-term survival in cancer patients.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JL participated in the design of the experiments, performed experiments and wrote the initial draft of the manuscript. BPZ designed experiments, interpreted results and wrote the final draft of the manuscript. Authors read and approved the final manuscript.